ORBi: Detailled Reference

Article (Scientific journals)

Sulphonylureas in the management of type 2 diabetes: To be or not to be?

Scheen, André

2021 • In Diabetes Epidemiology and Management, 1, p. 100002

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/312586

DOI
10.1016/j.deman.2021.100002

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

deman 2021 Sulphonylureas in the management of type 2 diabetes.pdf

Author postprint (1.65 MB)

Creative Commons License - Attribution, Non-Commercial, No Derivative

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Cardiovascular safety; Guidelines; Hypoglycaemia; Oral antidiabetic drug; Sulphonylurea

Abstract :

[en] Sulphonylureas (SUs) for a long time occupied an essential role in the management of type 2 diabetes (T2D) as an alternative or a complement to metformin. However, the launch of new oral antidiabetic drugs (OADs), firstly DPP-4 inhibitors (gliptins) and more recently SGLT2 inhibitors (gliflozins), has markedly changed the scene. Indeed, in contrast to SUs, these new OADs (of course more expensive) offer the advantage of a very low risk of hypoglycaemia and a beneficial impact on bodyweight. Furthermore, while gliptins showed good cardiovascular safety, gliflozins have proven to exert both a cardiovascular and renal protection in patients at high risk. This article discusses the current place to be reserved to SUs in the treatment of T2D, after a short recall about the risk of hypoglycaemia and the cardiovascular safety. Contrasted positions still remain in the international literature which translate into different guidelines between countries, especially due to economic constraints. SUs keep a place in the management of T2D, yet it becomes more and more limited. For sure, SU should be avoided among elderly frailty people and patients at high risk of hypoglycaemia.

Disciplines :

Endocrinology, metabolism & nutrition
Pharmacy, pharmacology & toxicology

Author, co-author :

Scheen, André ; Centre Hospitalier Universitaire de Liège - CHU > > Service de diabétologie, nutrition, maladies métaboliques

Language :

English

Title :

Sulphonylureas in the management of type 2 diabetes: To be or not to be?

Publication date :

2021

Journal title :

Diabetes Epidemiology and Management

eISSN :

2666-9706

Volume :

1

Pages :

100002

Peer reviewed :

Peer Reviewed verified by ORBi

Additional URL :

https://www.sciencedirect.com/science/article/pii/S2666970621000020

Available on ORBi :

since 01 February 2024

Statistics

Number of views

2 (1 by ULiège)

Number of downloads

4 (0 by ULiège)

More statistics

Scopus citations^®

6

Scopus citations^®
without self-citations

5

OpenCitations

4

Bibliography

Levine, R., Sulfonylureas: background and development of the field. Diabetes Care 7:Suppl 1 (1984), 3–7.
Groop, L.C., Sulfonylureas in NIDDM. Diabetes Care 15 (1992), 737–754.
Scheen, A.J., Lefebvre, P.J., Oral antidiabetic agents. A guide to selection. Drugs 55 (1998), 225–236.
Scheen, A.J., The safety of gliptins : updated data in 2018. Expert Opin Drug Saf 17 (2018), 387–405.
Scheen, A.J., An update on the safety of SGLT2 inhibitors. Expert Opin Drug Safety 18 (2019), 295–311.
Scheen, A.J., Cardiovascular effects of new oral glucose-lowering agents: DPP-4 and SGLT-2 inhibitors. Circ Res 122 (2018), 1439–1459.
Scheen, A.J., Sodium-glucose co-transporter type 2 inhibitors for the treatment of type 2 diabetes mellitus. Nature Rev Endocrinol 16 (2020), 556–577.
Brady, P.A., Terzic, A., The sulfonylurea controversy: more questions from the heart. J Am Coll Cardiol 31 (1998), 950–956.
Brady, P.A., Jovanovic, A., The sulfonylurea controversy: much ado about nothing or cause for concern?. J Am Coll Cardiol 42 (2003), 1022–1025.
Abdelmoneim, A.S., Eurich, D.T., Light, P.E., Senior, P.A., Seubert, J.M., Makowsky, M.J., et al. Cardiovascular safety of sulphonylureas: over 40 years of continuous controversy without an answer. Diabetes Obes Metab 17 (2015), 523–532.
Pop, L.M., Lingvay, I., The infamous, famous sulfonylureas and cardiovascular safety: much ado about nothing?. Curr Diabetes Rep, 17, 2017, 124.
Scheen, A.J., Cardiovascular safety of DPP-4 inhibitors compared to sulphonylureas : results of randomized controlled trials and observational studies. Diabetes Metab 44 (2018), 386–392.
Scheen, A.J., Challenging 2019 ESC guidelines for the management of type 2 diabetes. Diabetes Metab 46 (2020), 181–185.
Monami, M., Dicembrini, I., Kundisova, L., Zannoni, S., Nreu, B., Mannucci, E., A meta-analysis of the hypoglycaemic risk in randomized controlled trials with sulphonylureas in patients with type 2 diabetes. Diabetes Obes Metab 16 (2014), 833–840.
Tseng, C.L., Soroka, O., Maney, M., Aron, D.C., Pogach, L.M., Assessing potential glycemic overtreatment in persons at hypoglycemic risk. JAMA Intern Med 174 (2014), 259–268.
Scheen, A.J., DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials. Diabetes Metab 38 (2012), 89–101.
Zhang, Y., Hong, J., Chi, J., Gu, W., Ning, G., Wang, W., Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a meta-analysis from randomized clinical trials. Diabetes Metab Res Rev 30 (2014), 241–256.
Detournay, B., Halimi, S., Robert, J., Deschaseaux, C., Dejager, S., Hypoglycemia hospitalization frequency in patients with type 2 diabetes mellitus: a comparison of dipeptidyl peptidase 4 inhibitors and insulin secretagogues using the French health insurance database. Vasc Health Risk Manag 11 (2015), 417–425.
Chen, Z., Li, G., Sodium-glucose co-transporter 2 inhibitors compared with sulfonylureas in patients with type 2 diabetes inadequately controlled on metformin: a meta-analysis of randomized controlled trials. Clin Drug Investig 39 (2019), 521–531.
Shorr, R.I., Ray, W.A., Daugherty, J.R., Griffin, M.R., Individual sulfonylureas and serious hypoglycemia in older people. J Am Geriatr Soc 44 (1996), 751–755.
Andersen, S.E., Christensen, M., Hypoglycaemia when adding sulphonylurea to metformin: a systematic review and network meta-analysis. Br J Clin Pharmacol 82 (2016), 1291–1302.
Schernthaner, G., Grimaldi, A., Di Mario, U., Drzewoski, J., Kempler, P., Kvapil, M., et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest 34 (2004), 535–542.
Patel, A., MacMahon, S., Chalmers, J., Neal, B., Billot, L., Woodward, M., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358 (2008), 2560–2572.
Douros, A., Yin, H., Yu, O.H.Y., Filion, K.B., Azoulay, L., Suissa, S., Pharmacologic differences of sulfonylureas and the risk of adverse cardiovascular and hypoglycemic events. Diabetes Care 40 (2017), 1506–1513.
Douros, A., Dell'Aniello, S., Yu, O.H.Y., Filion, K.B., Azoulay, L., Suissa, S., Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study. BMJ, 362, 2018, k2693.
Zoungas, S., Patel, A., Chalmers, J., de Galan, B.E., Li, Q., Billot, L., et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 363 (2010), 1410–1418.
University Group Diabetes Program, A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes: sections I and II. Diabetes 19 (1970), 747–830.
University Group Diabetes Program, A study of the effects of hypoglycemia agents on vascular complications in patients with adult-onset diabetes. VI. Supplementary report on nonfatal events in patients treated with tolbutamide. Diabetes 25 (1976), 1129–1153.
UKPDS Group, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998), 837–853.
UK Prospective Diabetes Study (UKPDS) Group, Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352 (1998), 854–865.
Rao, A.D., Kuhadiya, N., Reynolds, K., Fonseca, V.A., Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies. Diabetes Care 31 (2008), 1672–1678.
Farah, D., Leme, G.M., Eliaschewitz, F.G., Fonseca, M.C.M., A safety and tolerability profile comparison between dipeptidyl peptidase-4 inhibitors and sulfonylureas in diabetic patients: a systematic review and meta-analysis. Diabetes Res Clin Pract 149 (2019), 47–63.
Azoulay, L., Suissa, S., Sulfonylureas and the risks of cardiovascular events and death: a methodological meta-regression analysis of the observational studies. Diabetes Care 40 (2017), 706–714.
Monami, M., Genovese, S., Mannucci, E., Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 15 (2013), 938–953.
Bain, S., Druyts, E., Balijepalli, C., Baxter, C.A., Currie, C.J., Das, R., et al. Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: a Bayesian meta-analysis of survival data. Diabetes Obes Metab 19 (2017), 329–335.
Leiter, L.A., Latest evidence on sulfonylureas: what's new?. Diabetes Ther 11 (2020), 15–22.
Zoungas, S., ADVANCE in context: the benefits, risks and feasibility of providing intensive glycaemic control based on gliclazide modified release. Diabetes Obes Metab 22:Suppl 2 (2020), 5–11.
Vaccaro, O., Masulli, M., Nicolucci, A., Bonora, E., Del Prato, S., Maggioni, A.P., et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinol 5 (2017), 887–897.
Scheen, A.J., Outcomes and lessons from the PROactive study. Diabetes Res Clin Pract 98 (2012), 175–186.
Rosenstock, J., Kahn, S.E., Johansen, O.E., Zinman, B., Espeland, M.A., Woerle, H.J., et al. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial. JAMA 322 (2019), 1155–1166.
Rosenstock, J., Perkovic, V., Johansen, O.E., Cooper, M.E., Kahn, S.E., Marx, N., et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA 321 (2018), 69–79.
Riveline, J.P., Danchin, N., Ledru, F., Varroud-Vial, M., Charpentier, G., Sulfonylureas and cardiovascular effects: from experimental data to clinical use. Available data in humans and clinical applications. Diabetes Metab 29 (2003), 207–222.
Ferrannini, E., DeFronzo, R.A., Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. Eur Heart J 36 (2015), 2288–2296.
Simpson, S.H., Lee, J., Choi, S., Vandermeer, B., Abdelmoneim, A.S., Featherstone, T.R., Mortality risk among sulfonylureas: a systematic review and network meta-analysis. Lancet Diabetes Endocrinol 3 (2015), 43–51.
Singh, A.K., Singh, R., Is gliclazide a sulfonylurea with difference? A review in 2016. Expert Rev Clin Pharmacol 9 (2016), 839–851.
Colagiuri, S., Matthews, D., Leiter, L.A., Chan, S.P., Sesti, G., Marre, M., The place of gliclazide MR in the evolving type 2 diabetes landscape: a comparison with other sulfonylureas and newer oral antihyperglycemic agents. Diabetes Res Clin Pract 143 (2018), 1–14.
Genuth, S., Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? No, it's time to move on!. Diabetes Care 38 (2015), 170–175.
Abrahamson, M.J., Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? Yes, they continue to serve us well!. Diabetes Care 38 (2015), 166–169.
Khunti, K., Chatterjee, S., Gerstein, H.C., Zoungas, S., Davies, M.J., Do sulphonylureas still have a place in clinical practice?. Lancet Diabetes Endocrinol 6 (2018), 821–832.
Webb, D.R., Davies, M.J., Jarvis, J., Seidu, S., Khunti, K., The right place for sulphonylureas today. Diabetes Res Clin Pract, 157, 2019, 107836.
Mohan, V., Cooper, M.E., Matthews, D.R., Khunti, K., The standard of care in type 2 diabetes: re-evaluating the treatment paradigm. Diabetes Ther 10 (2019), 1–13.
Khunti, K., Hassanein, M., Lee, M.K., Mohan, V., Amod, A., Role of gliclazide MR in the management of type 2 diabetes: report of a symposium on real-world evidence and new perspectives. Diabetes Ther 11 (2020), 33–48.
Wexler, D.J., Sulfonylureas and cardiovascular safety: the final verdict?. JAMA, 2019, 10.1001/jama.2019.14533 September 19.
Amod, A., The place of sulfonylureas in guidelines: why are there differences?. Diabetes Ther 11 (2020), 5–14.
Diop, S.N., Baldé, N., Sidibé, A.T., La bithérapie antidiabétique orale en pratique médicale courante en Afrique subsaharienne : résultats d'une étude observationnelle multicentrique sur six mois. Med Mal Metab 12 (2018), 306–312.
Kalra, S., Bahendeka, S., Sahay, R., Ghosh, S., Md, F., Orabi, A., et al. Consensus recommendations on sulfonylurea and sulfonylurea combinations in the management of type 2 diabetes mellitus - International Task Force. Indian J Endocrinol Metab 22 (2018), 132–157.
Roglic, G., Norris, S.L., Medicines for treatment intensification in type 2 diabetes and type of insulin in type 1 and type 2 diabetes in low-resource settings: synopsis of the World Health Organization Guidelines on second- and third-line medicines and type of insulin for the control of blood glucose levels in nonpregnant adults with diabetes mellitus. Ann Intern Med 169 (2018), 394–397.
Aschner, P., New IDF clinical practice recommendations for managing type 2 diabetes in primary care. Diabetes Res Clin Pract 132 (2017), 169–170.
International Diabetes Federation, Recommendations for managing type 2 diabetes in primary care. 2017, International Diabetes Federation, Belgium (latest accessed Feburary 4, 2021) https://www.idf.org/e-library/guidelines/128-idf-clinical-practice-recommendations-for-managing-type-2-diabetes-in-primary-care.html.
Davies, M.J., D'Alessio, D.A., Fradkin, J., Kernan, W.N., Mathieu, C., Mingrone, G., et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 61 (2018), 2461–2498.
Buse, J.B., Wexler, D.J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., et al. update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2020:63 (2019), 221–228.
Haute Autorité de Santé (HAS), Stratégie médicamenteuse du contrôle glycémique du diabète de type 2 : recommandations. 2013 [Epub]; Available from: http://www.has-sante.fr/portail/upload/docs/application/pdf/2013-02/10irp04_reco_diabete_type_2.pdf (latest accessed Feburary 4, 2021).
Consoli, A., Czupryniak, L., Duarte, R., Jermendy, G., Kautzky-Willer, A., Mathieu, C., et al. Positioning sulphonylureas in a modern treatment algorithm for patients with type 2 diabetes: expert opinion from a European consensus panel. Diabetes Obes Metab 22 (2020), 1705–1713.
Diop, S.N., Djrolo, F., Sidibé, A.T., Baldé, N.M., Monabeka, H.G., Epaka, M.E., et al. Consensus pour la prise en charge de l'hyperglycémie dans le diabète de type 2 en Afrique subsaharienne. Rédigé par un groupe d'experts africains du diabète. Med Mal Metab 13 (2019), 210–216.

Similar publications